No Detail Found!

Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.

Author(s)
Tao Li Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Yundong Qu Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Yan Wang Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Chunlei Lin Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Baohua Yang Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Lei Wang Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan 250033, China
Abstract
Objective: To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients. Study Design: An observational study. Place and Duration of Study: Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Jinan, China, from October 2008 to October 2016. Methodology: HBV-related cirrhotic patients with antiviral treatment for at least 12 months were consecutively included. Propensity score matching analysis was performed to improve comparability of the data from both entecavir group and the control group. Log-rank test was used to compare influence of various nucleos(t)ide analogs (NAs) for incidence of HCC. Independent risk factors were estimated by multivariable Cox proportional hazards models. Results: The total cohort included 207 HBV-related cirrhotic patients, of which 83 patients were treated with entecavir initially. The present study found no statistical difference for the incidence of HCC between entecavir group and the control group in the total cohort (p=0.525). However, the difference became statistically significant (p=0.014) after propensity score matching. Number needed to treat (NNT) were 8 patients, 6 patients and 3 patients at years 2, 3 and 4, respectively. Multivariable Cox regression in propensity score matching cohort revealed older age (HR: 1.066, p=0.041), NAs of low generic barrier (HR: 6.944, p=0.016), NAs resistance (HR: 3.648, p=0.041), and lower platelet counts (<80x109/L) (HR: 6.718, p=0.009) as independent risk factors for HCC incidence. Conclusion: Entecavir is more efficient in reducing the incident HCC risk for HBV-related cirrhotic patients in comparison to low genetic barrier NAs.
Publication Details
Page(s) 317-323
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 4, Year: 2019

Request the full text from PASTIC

References
SarinSK,KumarM,LauGK,AbbasZ,ChanHL,ChenCJ, 2016.Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update,Hepatol Int 10 1 -98
LiawYF,SungJJ,ChowWC,FarrellG,LeeCZ,YuenH, 2004.Lamivudine for patients with chronic hepatitis B and advanced liver disease,N Engl J Med 351 1521 -31
ChangTT,LaiCL,Kew YoonS,LeeSS,CoelhoHS,CarrilhoFJ, 2010.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B,Hepatology 51 422 -30
HosakaT,SuzukiF,KobayashiM,SekoY,KawamuraY,SezakiH, 2013.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection,Hepatology 58 98 -107
-, 2015.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection (, -
HiramatsuN,YamadaR,TakeharaT., 2016.The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients,J Gastroenterol Hepatol 31 546 -52
KobashiH,MiyakeY,IkedaF,YasunakaT,NishinoK,MoriyaA, 2011.Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine,Hepatol Res 41 405 -16
LimYS,HanS,HeoNY,ShimJH,LeeHC,SuhDJ, 2014.Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine,Gastroenterology 147 152 -61
KimSS,HwangJC,LimSG,AhnSJ,CheongJY,ChoSW, 2014.Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis,Am J Gastroenterol 109 1223 -33
AltmanDG,AndersenPK, 1999.Calculating the number needed to treat for trials where the outcome is time to an event,BMJ 319 1492 -5
LoKJ,TongMJ,ChienMC,TsaiYT,LiawYF,YangKC, 1982.The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan,J Infect Dis 146 205 -10
KatoY,NakataK,OmagariK,FurukawaR,KusumotoY,MoriI, 1994.Risk of hepatocellular carcinoma in patients with cirrhosis in Japan,Cancer 74 2234 -8
PapatheodoridisGV,LamperticoP,ManolakopoulosS,LokA, 2010.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review,J Hepatol 53 348 -56
TawadaA,KandaT,ImazekiF,YokosukaO, 2016.Prevention of hepatitis B virus-associated liver diseases by antiviral therapy,Hepatol Int 10 574 -93
BiJ,ZhangZ,QinE,HouJ,LiuS,LiuZ, 2017.Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis,Oncotarget 8 96725 -31
ZoutendijkR,ReijndersJG,ZoulimF,BrownA,MutimerDJ,DeterdingK, 2013.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis,Gut 62 760 -5
GordonSC,LameratoLE,RuppLB,LiJ,HolmbergSD,MoormanAC, 2014.Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population,Clin Gastroenterol Hepatol 12 885 -93
ArendsP,SonneveldMJ,ZoutendijkR,CareyI,BrownA,FasanoM, 2015.Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians,Gut 64 1289 -95
RaptiI,Hadziyannis S, 2015.Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues,World J Hepatol 7 1064 -73
PapatheodoridisGV,IdilmanR,DalekosGN,ButiM,ChiH,van BoemmelF, 2017.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B,Hepatology 66 1444 -53
ChangTT,GishRG,de ManR,GadanoA,SollanoJ,ChaoYC, 2006.A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B,N Engl J Med 354 1001 -10
YuJH,LeeJI, 2017.Current role of transient elastography in the management of chronic hepatitis B patients,Ultrasonography 36 86 -94
ChenCF,LeeWC,YangHI,ChangHC,JenCL,IloejeUH, 2011.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma,Gastroenterology 141 1240 -8
NamJY,ChangY,ChoH,KangSH,ChoYY,ChoEJ, 2018.Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B,J Viral Hepat 25 552 -60
KurokawaM,HiramatsuN,OzeT,YakushijinT,MiyazakiM,HosuiA, 2012.Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection,J Gastroenterol 47 577 -85
0

Citations

0

Downloads

162

Views